Unlock stock picks and a broker-level newsfeed that powers Wall Street.

China Regenerative Medicine International And 2 Other Promising Penny Stocks

In This Article:

Global markets have recently experienced significant shifts, with U.S. stocks rallying to record highs following election results that sparked hopes for economic growth and tax reforms. Amidst these broader market dynamics, penny stocks—often associated with smaller or newer companies—continue to offer intriguing opportunities for investors willing to explore beyond the mainstream. Despite being a somewhat outdated term, penny stocks can still represent potential growth avenues when backed by strong financial health and solid fundamentals.

Top 10 Penny Stocks

Name

Share Price

Market Cap

Financial Health Rating

Rexit Berhad (KLSE:REXIT)

MYR0.79

MYR136.84M

★★★★★★

BP Plastics Holding Bhd (KLSE:BPPLAS)

MYR1.25

MYR351.85M

★★★★★★

DXN Holdings Bhd (KLSE:DXN)

MYR0.46

MYR2.29B

★★★★★★

Lever Style (SEHK:1346)

HK$0.87

HK$552.27M

★★★★★★

Embark Early Education (ASX:EVO)

A$0.79

A$144.95M

★★★★☆☆

Seafco (SET:SEAFCO)

THB2.06

THB1.67B

★★★★★★

Wellcall Holdings Berhad (KLSE:WELLCAL)

MYR1.53

MYR761.86M

★★★★★★

ME Group International (LSE:MEGP)

£2.25

£847.72M

★★★★★★

Supreme (AIM:SUP)

£1.63

£190.08M

★★★★★★

Kelington Group Berhad (KLSE:KGB)

MYR2.93

MYR2.02B

★★★★★☆

Click here to see the full list of 5,754 stocks from our Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

China Regenerative Medicine International

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: China Regenerative Medicine International Limited is an investment holding company that provides healthcare products and services in Hong Kong and the People's Republic of China, with a market cap of HK$139.96 million.

Operations: The company's revenue primarily comes from its operations in Hong Kong, amounting to HK$53.48 million.

Market Cap: HK$139.96M

China Regenerative Medicine International Limited, with a market cap of HK$139.96 million, is currently unprofitable but has managed to maintain a positive free cash flow and sufficient cash runway for over three years. Despite its high net debt to equity ratio of 156.6% and increased share volatility, the company has reduced losses significantly over the past five years. Recent earnings reports show sales of HK$59.79 million for the first half of 2024, down from HK$74.22 million in the previous year, yet net income improved slightly to HK$16.83 million from HK$12.76 million due to cost management efforts.

SEHK:8158 Financial Position Analysis as at Nov 2024
SEHK:8158 Financial Position Analysis as at Nov 2024

Simat Technologies

Simply Wall St Financial Health Rating: ★★★★★★